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1  | INTRODUC TION
Increasing life expectancy of global demographical trends revealed 
not only an estimated increase in a world population of 50 million 
annually (Srinivasan et al., 2017), but as populations are aging, the 
prevalence of disabling disease and the related intake of medica-
tions increases steeply with age (Collaborators, 2017). Even though 
implant- supported rehabilitations are a highly successful treat-
ment option with predictable long- term success rates after 10 and 
20 years (Chappuis et al., 2013; Chappuis et al., 2018), the possible 
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Abstract
Objectives: The aim of this systematic review was to investigate the association be-
tween the intake of systemic medications that may affect bone metabolism and their 
subsequent impact on implant failures.
Material and methods: Electronic and manual literature searches were conducted. 
Implant failure (IF) was the primary outcome, while biological/mechanical and the 
causes/timing associated with IF were set as secondary outcomes. Meta- analyses for 
the binary outcome IF and odds ratio were performed to investigate the association 
with medications.
Results: A final selection of 17 articles was screened for qualitative assessment. As 
such, five studies focused on evaluating the association of implant failure and non- 
steroidal anti- inflammatory drugs (NSAIDs), two on selective serotonin reuptake in-
hibitors (SSRIs), two on proton pump inhibitors (PPIs), seven on bisphosphonates 
(BPs), and one on anti- hypertensives (AHTNs). For PPIs, the fixed effect model esti-
mated a difference of IF rates of 4.3%, indicating significantly higher IF rates in the 
test compared to the control group (p < 0.5). Likewise, for SSRIs, the IF was shown to 
be significantly higher in the individuals taking SSRIs (p < 0.5) as estimated a differ-
ence of 7.5%. No subset meta- analysis could be conducted for AHTNs medications as 
only one study fulfilled the inclusion criteria, which revealed an increased survival 
rate of AHTN medication. None of the other medications yielded significance.
Conclusions: The present systematic review showed an association of PPIs and SSRIs 
with an increased implant failure rate. Hence, clinicians considering implant therapy 
should be aware of possible medication-related implant failures.
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biological complications, dental implant, drug, endosseous implant, epidemiology, failure, 
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impact of disabling systemic diseases on implant rehabilitation has 
been described in systematic reviews (Beikler and Flemmig, 2003; 
Bornstein et al., 2009; Diz et al., 2013; Donos and Calciolari, 2014; 
Mombelli and Cionca, 2006; Scully et al., 2007). These uncontrolled 
medical conditions may have an effect at the local or systemic level 
and have been associated with an increased risk of breakdown of 
the peri- implant tissues (Heitz- Mayfield & Huynh- Ba, 2009; Heitz- 
Mayfield, Needleman, Salvi & Pjetursson, 2014; Lang et al., 2011; 
Lang et al., 2004; Monje, Catena & Borgnakke, 2017). Systemic dis-
eases as obesity, arthritis, and other chronic diseases induce a low- 
grade systemic inflammatory condition associated with high levels 
of circulating pro- inflammatory cytokines that favor the chemotaxis 
and activations of monocytes, neutrophils, and adipose tissue mac-
rophages, which may ultimately contribute to the establishment of 
bone loss and peri- implant disease (Hill, Reid Bolus & Hasty, 2014; 
Straub et al., 2015; Wei, Tarling, McMillen, Tang & LeBoeuf, 2015).
In addition to uncontrolled systemic diseases itself, the sys-
temic intake of medication such as thiazide diuretics, β- blockers, 
anti- inflammatory drugs, proton pump inhibitors, or serotonin re-
uptake inhibitors have shown to further modulate bone metabo-
lism (Abrahamsen and Vestergaard, 2013; Brater, 1998, 2011; de 
Vernejoul et al., 2012; Geusens et al., 2013; Haney & Warden, 2008; 
Vestergaard, 2008; Wiens et al., 2006). These medication- related side 
effects are less understood and may exert an important influence on 
implant- related outcomes. Therefore, in recent demographical trends 
with an aging population, a comprehensive assessment and under-
standing of the patient’s medical background is important, as related 
medication- specific side effects are able to influence bone metabo-
lism (Insua, Monje, Wang & Miron, 2017; Kremers et al., 2016).
Osteocytes play a crucial role in bone turnover processes, such 
as osseointegration, and are a major source of receptor activator of 
nuclear factor- kappaB ligand (RANKL) in bone (O’Brien, Nakashima 
& Takayanagi, 2013), which is required for osteoclast differentiation 
and activation (Kong et al., 1999). Hence, in case of medication- 
induced disruption of osteocyte metabolic activities, adequate 
peri- implant bone remodeling in early stages of healing may be 
jeopardized. Likewise, anti- hypertensive medications, such as beta- 
blockers or angiotensin- converting enzyme inhibitors, have been 
shown to inhibit the normal physiologic function of osteoclasts on 
bone by blocking surface β- 2 adrenergic receptors, which may result 
in shifting the balance toward bone formation by blocking the renin- 
angiotensin system (Brater, 1998, 2011). Furthermore, the action of 
serum serotonin reuptake inhibitors (SSRIs) on certain receptors and 
serotonin transporters, such as 5- HT1B, 5- HT2B or 5- HT2C, may 
result in a direct detrimental effect on bone metabolism by increas-
ing osteoclast differentiation (Haney & Warden, 2008; Vestergaard, 
2008), which may negatively impact the process of osseointegration.
A comprehensive assessment and understanding of the patient’s 
medical background and current medications is important for life-
long implant- supported rehabilitations. Therefore, the aim of this 
systematic review was to investigate the association between the 
intake of medications that may affect bone metabolism and implant 
outcomes.
2  | MATERIAL AND METHODS
This systematic review was conducted according to the guidelines 
of the Preferred Reporting Items of Systematic Reviews and Meta- 
analyses (PRISMA) statement (Moher, Liberati, Tetzlaff, Altman, 
& PRISMA Group, 2009). The review protocol was registered in 
PROSPERO (International Prospective Register of Systematic 
Reviews) hosted by the UK’s National Institute for Health Research 
(NHS), University of York, Centre for Reviews and Dissemination, 
under the code CRD42017067170 (https://www.crd.york.ac.uk/
PROSPERO/display_record.asp?ID=CRD42017067170)
2.1 | Focused questions
1. Is there an association between medication intake and im-
plant outcomes (i.e., implant failure)? (Primary question)—If 
answer is “yes,” then:
2. What are these medications and the respective dosage associated 
with implant failure? (Secondary question)
3. Does implant failure occur in the early stages of healing or after 
osseointegration is attained (i.e., biological complications) 
(Secondary question)
4. Are these patients associated with more mechanical 
complications?
5. Are there any other confounders associated with implant failure 
in medicated patients? (Secondary question)
6. What is the strength of the evidence for associations between 
medication intake and implant failure? (Secondary question)
2.2 | PECO question (population, exposure, 
comparison, and outcome measures) (Stone  2002).
P: Completely or partially edentulous human adults wearing implant- 
supported prostheses.
E: Regular intake of oral, intramuscular, or intravenous medications/
drugs that may affect bone metabolism.
C: Individuals not taking any known relevant medication (Non- specific 
medication dependent for the treatment of a medical condition.)
O: Dental implant failure (primary outcome), peri- implant marginal 
bone loss (secondary outcome), and biological (i.e., peri- implant mu-
cositis or peri- implantitis) or mechanical complications reported at 
the implant or patient level (secondary outcomes).
2.3 | Eligibility criteria
Prospective or retrospective cohort, case–control, cross- sectional, or 
randomized controlled trials exploring the association of medication 
intake and implant failure in humans were considered for inclusion.
2.3.1 | Literature search protocol
Electronic and manual literature searches were conducted inde-
pendently by two authors (AM, VC) in several databases, including 
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PubMed, MEDLINE (OVID), EMBASE (OVID), Cochrane Central 
Register of Controlled Trials (Cochrane Library), Cochrane Oral 
Health Group Trials Register (Cochrane Library), Web of Science 
(Thomson Reuters), and SciVerse (Elsevier). Studies published up 
to May 2017 were considered, without any language restrictions. 
For the PubMed library, combinations of controlled terms (MeSH 
and EMTREE) and keywords were used whenever possible, and 
other terms not indexed as MeSH and filters were also applied. The 
search strategy used was ((((“dental implants” OR ((“dental implan-
tation, endosseous”) OR “dental implantation, endosseous”[MeSH 
Terms]) AND “abnormalities, drug- induced”[MeSH Terms]) OR 
“serotonin uptake inhibitors”[MeSH Terms]) OR “anti- inflammatory 
agents, non- steroidal”[MeSH Terms]) OR “adrenergic beta- 
antagonists”[MeSH Terms]) OR “angiotensin- converting enzyme 
inhibitors”[MeSH Terms]) OR “proton pump inhibitors”[MeSH 
Terms]) OR “bisphosphonates”[MeSH Terms]) OR “bisphosphonate- 
associated osteonecrosis of the jaw”[MeSH Terms]) AND “survival 
analysis”[MeSH Terms] AND ((Classical Article[ptyp] OR Clinical 
Study[ptyp] OR Clinical Trial[ptyp]) AND “humans”[MeSH Terms]). 
Moreover, a less specific screening using non- MeSH index terms 
was conducted to ascertain the articles to be evaluated. The screen-
ing strategy was as follows: ((((medication- related[Title/Abstract] 
OR drug- related[Title/Abstract]) OR bisphosphonate- related[Title/
Abstract]) AND dental implant failure[Title/Abstract]) OR dental im-
plant survival[Title/Abstract]) OR ((“dental implants”[MeSH Terms] 
OR (“dental”[All Fields] AND “implants”[All Fields]) OR “dental 
implants”[All Fields] OR (“dental”[All Fields] AND “implant”[All Fields]) 
OR “dental implant”[All Fields]) AND biological complication[Title/
Abstract]) OR ((“dental implants”[MeSH Terms] OR (“dental”[All 
Fields] AND “implants”[All Fields]) OR “dental implants”[All Fields] 
OR (“dental”[All Fields] AND “implant”[All Fields]) OR “dental 
implant”[All Fields]) AND technical complication[Title/Abstract]). 
On the other side, for the EMBASE Library, the key terms used were 
as follows: (‘dental implant’/exp OR ‘dental implants’) OR (‘endosse-
ous implant’ OR ‘endosseous implants’) AND (‘medication- related’/
exp OR ‘medications- related’) OR ‘drug- related’/exp OR ‘drugs- 
related’ AND ‘implant failure’/de AND ‘human’/de AND ‘article’/it. 
For searching the remaining electronic databases, combinations of 
‘medication- related’ OR ‘drug- related’ AND ‘dental implant’ AND 
‘failure’ OR ‘survival’, limited to titles and abstracts.
Additionally, the “grey literature” available at the New York 
Academy of Medicine Grey Literature Report (http://greylit.org) and 
the register of clinical studies hosted by the US National Institutes 
of Health (www.clinicaltrials.gov) was searched to further identify 
potential candidates for inclusion. Moreover, the authors conducted 
manual searches in selected journal issues published between 
January 2017 and August 2017 (i.e., Journal of Dental Research, 
Journal of Clinical Periodontology, Journal of Periodontology, Journal of 
Oral and Maxillofacial Implants, Clinical Oral Implants Research, Clinical 
Implant Dentistry and Related Research, The International Journal of 
Periodontics & Restorative Dentistry, and the International Journal of 
Oral and Maxillofacial Surgery). Bibliographies of identified relevant 
publications were also cross- searched.
2.4 | Literature selection and data 
extraction protocol
Corresponding authors were contacted for clarifying information 
about studies lacking clear information. Two independent exam-
iners (AM and VC) extracted the data. Data of interest were ex-
tracted based on the general study characteristics (authors and 
year of publication, type of study), population characteristics 
(number of participants), implant and prosthetic characteristics 
(number of implants, implant location, type of prosthetic loading, 
follow- up period after implant placement), and primary and sec-
ondary outcomes.
2.5 | Risk of bias
The methodological and reporting quality of all selected full- text re-
ports was assessed according to the STROBE statement for observa-
tional studies (Shea et al. 2009; von Elm et al. 2007). Moreover, the 
Assessment of Multiple Systematic Reviews guidelines (AMSTAR) 
was followed (Shea et al. 2009).
2.6 | The Newcastle–Ottawa Scale for assessing the 
quality of non- randomized studies (NOS)
Assessment of the quality of non- randomized, non- interventional 
studies is essential for proper evaluation of the evidence provided 
by each study. We followed the Newcastle–Ottawa System (NOS) 
protocol (Wells et al. 2011). The items evaluated were selection of 
study groups, comparability of participants, and outcome. Each in-
cluded study received a maximum score of 13 points for cohort stud-
ies and 10 points for case–control studies (Table S1). The Cohen’s 
kappa coefficient was calculated to assess inter- rater agreement 
(AM and GAO).
2.7 | Statistical analysis
The statistical analysis was performed with the statistical software 
package R 3.1.1 (The R Project for Statistical Computing, www.r-
project.org). The feasibility of conducting specific quantitative 
analyses (meta- analyses) was explored. If feasible, the additional 
package “meta” was used. Meta- analyses for the binary outcome im-
plant failure (IF) were performed. The numbers of implants in both 
experimental and control groups were extracted directly from the 
data; the numbers of failures had to be calculated from the reported 
failure rates. As aforementioned, studies with missing information 
were excluded from the quantitative analysis.
The odds ratio of failure in the test group (individuals in- taking 
medications) vs. failure in the control group (individuals not taking 
any known relevant medication) was analyzed. Estimated odds ra-
tios together with 95% confidence intervals were calculated for 
every included study as well as for the pooled set of studies. The 
studies were pooled using the inverse variance method. Both fixed 
and random weights were applied, yielding two different estimates 
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of the population odds ratio. The heterogeneity among the included 
studies was measured computing I2 and a p value for the null of ho-
mogeneous studies. This p value was compared to the level of sig-
nificance of 5%.
3  | RESULTS
3.1 | Study selection (Figure 1)
A total of 430 entries were identified through the electronic search, 
and after removal of duplicates. The initial pool was not supple-
mented with any further article identified through manual search 
or cross- reference assessments. Of these 430, forty articles were 
assessed for full- text evaluation, resulting in a final selection of 17 
articles for qualitative assessment (Table 1) (Alissa et al., 2009; Al- 
Sabbagh, Robinson, Romanos & Thomas, 2015; Chrcanovic, Kisch, 
Albrektsson & Wennerberg, 2017a,b; Famili, Quigley & Mosher, 
2011; Grant, Amenedo, Freeman & Kraut, 2008; Jeffcoat et al., 
1995; Koka, Babu & Norell, 2010; Memon, Weltman & Katancik, 
2012; Reddy, Jeffcoat & Richardson, 1990; Siebert, Jurkovic, 
Statelova & Strecha, 2015; Urdaneta, Daher, Lery, Emanuel & 
Chuang, 2011; Winnett, Tenenbaum, Ganss & Jokstad, 2016; Wu 
et al., 2014, 2016, 2017; Zahid, Wang & Cohen, 2011). A total of 23 
articles did not meet the eligibility criteria and were subsequently 
excluded (Table 2).
The studies included for qualitative assessment were pooled ac-
cording to the medication category. As such, five studies were focused 
on evaluating the association of implant failure and non- steroidal anti- 
inflammatory drugs (NSAIDs) (Alissa et al., 2009; Jeffcoat et al., 1995; 
Reddy et al., 1990; Urdaneta et al., 2011; Winnett et al., 2016), two on 
selective serotonin reuptake inhibitors (SSRIs) (Chrcanovic et al., 2017b; 
Wu et al., 2014), two on proton pump inhibitors (PPIs) (Chrcanovic 
et al., 2017a; Wu et al., 2017), seven on oral bisphosphonates (BPs) (Al- 
Sabbagh et al., 2015; Famili et al., 2011; Grant et al., 2008; Koka et al., 
2010; Memon et al., 2012; Siebert et al., 2015; Zahid et al., 2011), and 
one on anti- hypertensives (AHTNs) (Wu et al., 2016).
3.2 | Studies methods
With regard to research methodology, the vast majority of the in-
cluded articles (12) were based on retrospective cohort studies (RC) 
(Chrcanovic et al., 2017a,b; Famili et al., 2011; Grant et al., 2008; 
Koka et al., 2010; Memon et al., 2012; Urdaneta et al., 2011; Winnett 
et al., 2016; Wu et al., 2014, 2016, 2017; Zahid et al., 2011), three 
were randomized controlled trials (RCT) (Alissa et al., 2009; Jeffcoat 
et al., 1995; Reddy et al., 1990), one prospective cohort (PC) (Siebert 
et al., 2015), and one case–control (CC) (Al- Sabbagh et al., 2015).
3.3 | Association of medication- related 
implant failure
Overall, five groups could be pooled according to the medica-
tion type. For hypertension- related medication- associated implant 
failure (i.e., beta- blockers or ACE inhibitors), only one study could 
be identified and accordingly, no subset meta- analysis could be car-
ried out. For NSAIDs, the analysis could not be performed, as the 
vast majority of studies reported no failures in any of the control or 
experimental groups. For PPIs, the homogeneity of the two included 
studies was rejected at the 5% level (I2 = 0.93, p < .01). Hence, the 
results should be interpreted carefully. Both the fixed effects and 
the random effects model estimated a difference of implant failure 
(IF) rates of 4.29% and 4.53%, meaning significantly higher IF rates in 
the test compared to the control group (p < .01) (Figure 2). Likewise, 
for SSRIs, the homogeneity of the two studies was rejected at the 
level 5% (p < .01). Both the fixed effects and the random effects 
model estimated a large positive difference of 7.48% and 7.50%, 
rendering significantly higher IF rates in the test compared to the 
control group (p < .01) (Figure 3). With regard to IF associated with 
the intake of BPs, one study (Al- Sabbagh et al., 2015) was excluded 
from the analysis due to missing IF in the control group. Using the 
IF rate as the primary outcome in the analysis, studies with a 0 IF 
rate in either the experimental or the control group were assigned 
a weight of 0, because the estimated standard deviation is 0. The 
remaining six studies were weighted and the estimated differences 
were	−0.13	in	the	fixed	effects	model	and	0.86	in	the	random	effects	
model (Figure 4). These results must be interpreted cautiously due 
to a high heterogeneity of I2 = 98% (p < .01 for the test of homoge-
neity among the included studies).
No analysis was conducted for secondary outcomes. Implant 
survival (IS) was redundant to the primary outcome IF, whereas mar-
ginal bone loss (MBL) and timing of failure (TF) were reported in too 
few studies.
3.4 | Odds ratio for implant failure according to the 
medication intake
No subset meta- analysis could be conducted for AHTNs medications 
as only one study fulfilled the inclusion criteria, which revealed an 
increased survival rate of AHTN medication. For PPIs, the homoge-
neity of the two studies could not be rejected at the 5% level (I2=0, 
p = 0.78). Both the fixed effects and the random effects model esti-
mate an odds ratio of a failure in the experimental group against a fail-
ure in the control group of 2.02. The corresponding 95% confidence 
interval does not contain 1.00, so there is a significant effect of the 
medication (p < .05) (Figure 2). Likewise, for SSRIs, the homogeneity 
of the two studies could be rejected at the 5% level (I2 = 0, p = .36). 
The fixed effects model estimated an odds ratio of IF in the experi-
mental group against failure in the control group of 2.92; the random 
effects model resulted in 3.00 (Figure 3). Thus, a significant effect of 
the experimental medication was found (p < .05). When analyzing oral 
BPs, one study (Al- Sabbagh et al., 2015) was excluded from the analy-
sis due to missing IF in the control group, as previously mentioned. 
For the remaining six studies, the homogeneity could not be rejected 
at the 5% level (I2 = 27, p = .24). The fixed effects model estimated an 
odds ratio of failure in the experimental group against failure in the 
control group of 1.11, while the random effects model indicated an 
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TABLE  1 On the medication- related implant failure: systematic review [In PDF format, this table is best viewed in two-page mode]
Authors 
(year)
Study 
design
Mean 
follow- up
Systemic 
condition Medication Dosage (mg/ml)
Therapy 
length 
(months)
Administration 
method
Subjects 
(n) Age (years)
Gender 
(M/F)
Implants 
(n)
Failure 
(month)
Marginal 
bone loss 
(mm)
Implant 
survival 
rate(%)
Implant 
failure 
rate (%) HR (95% CI)
Biological 
complications Comments
Wu et al. 
(2016)
RC 17.1 ± 16.6 Hypertension AM (beta- bloquers - 18.9%, 
thiazide diuretics - 5.4%, 
ACE inhibitors - 29.7%, 
ARBs - 24.3%, others 
- 21.6%)
NR NR Oral 142 57.7 ± 12.1 375/353 327 NR NR 99.4 0.6 0.12 
(0.03–0.49)
NR 1.  BA was performed more often in AH drug users (OR = 0.71)
2.  Age, gender, implant length, implant torque, implant loading 
and BA did not affect SR
3. HT patients not taking AH drugs had a failure of 4.7%
4.  Smoking was associated with increased implant failure  
(HR: 3.59)
ASA I- II NSM N N N 586 1172 NR NR 95.9 4.1 1 NR
Alissa et al. 
(2009)
RCT 6 ASA I- II NSAIDs (Ibuprophen) 600 mg 4×/day 7 d Oral 29 NR NR 41 N 1.09 ± 0.99 100 0 NR 0 1.  The multiple linear regression test showed that MBL was not 
SS associated with: age, gender, anatomic location, treatment 
group and examinerNSM N N N 29 48 N 1.19 ± 0.96 100 0 NR 0
Jeffcoat 
et al. (1995)
RCT 12 ASA I- II NSAIDS (Flurbiprofen) 50 mg 2× day 3 mo Oral 29 47.2 NR N 0.65 100 0 NR NR 1.  Quantitative digital substraction radiography was used to 
assess bone mass loss 2.Placebo and low- dose flurbiprophen 
lost a mean of 11.2 ± 3.89 and 14.6 ± 3.69 mg, respectively.
3.  High- dose flurbiprophen lost a mean of 2.60 ± 4.13 mg
4. Smooth surface dental implants
Flurbiprofen 100 mg 2× day 3 mo Oral N 1.6 100 0 NR
NSM N N N N 1.1 100 0 NR
Winnett 
et al. (2014)
RC NR NC NSAIDS (Ibuprophen) 600 mg 4× day 2w Oral 60 NR NR 273 Early:72%; 
late:28%
NR 56 44 NR NR 1. Retrospective data based on university setting. 
2.  The NSAIDs experienced 3.2× more case of radiographic 
bone loss 1/2 and 1.9× greater than 1/2 of the implant height
NSM N N N 44 203 Early:65%; 
late:35%
62 38 NR
Urdaneta 
et al. (2011)
RC 70.7 Arthristis, 
CDV 
prevention
NSAIDS (Ibuprophen, 
celecoxib, acetylsalicydic, 
rofecoxib, nabumetone, 
naproxen, etodolac)
Ibuprophen (600–1600 mg), 
celecoxib (200 mg), 
acetylsalicydic (325 mg), 
rofecoxib (25 mg), nabumetone 
(500 mg), naproxen (375 mg), 
etodolac (400 mg)
Daily Oral 13 NR NR 61 NR 0.06 100 0 NR NR 1. Study on extra- short locking- taper implants 
2. Main goal was to analyze crestal bone gain 
3.  Crestal bone gain was significantly correlated with type of 
opposing structure, tooth, type of restoration, crown 
cemented on prefabricated titanium abutment, hydroxiapa-
tite coating, implant site and daily intake of NSADS (p = 0.04) 
4.  Similar bone gain was observed in men/woman, maxilla/
mandibleASA I- II NSM N N n 68 265 0.42 97.74 2.26 NR NR
Wu et al. 
(2016)
RC 16.6 ± 16.3 Gastric function 
abnormalitis
PPI NR NR Oral 58 56.6 ± 13.7 369/430 133 NR NR 93.2 6.8 2.73 
(1.10–6.78)
NR 1.  Large RC study with different implan ttypes, protocols and 
grafting procedures 
2. NSAIDs were taken more by PPI users (OR = 1.73) 
3. Smoking was associated with IF (p = 0.001) 
4.  Patients gender, age implant length, and bone augmentation 
had no significant association with IF
ASA I- II NSM N N n 741 1,640 96.8 3.2 1
Wu et al. 
(2014)
RC 36 Depressive 
condition
SSRIs (citalopram, dapoxetine, 
escitalopram, fluoxetine, 
fluvoxamine, indalpine, 
paroxetine, sertraline, 
venlafaxine, zimeline)
NR NR Oral 50 56.4 ± 13.7 198/292 94 4–14 mo NR 89.4 10.6 6.28 
(1.25–31.61)
NR 1.  Large RC study with different implan ttypes, protocols and 
grafting procedures 
2.  Smoking habit (p = 0.01)and small implant diameters 
(p = 0.02) were associated with higher IF 
3.  Bone augmentation was associated with higher implant 
failure 
ASA I- II NSM N N N 440 882 95.4 4.6 1
Reddy et al. 
(1990)
RCT 4 ASA I- II NSAIDS (Flurbiprofen) 100 mg 2× day 4 mo Oral NR NR NR NR NR NR 100 0 NR NR 1.  Main goal was to assess the peri- implant bone remodeling 
testing the feasability of digital substraction radiography 
2.  No data on patientients demographics nor implant 
characteristics 
3.  Individuals intaking the NSAIDs experienced greater 
peri- implant bone density during healing
NSM N N N 100 0 NR
Chrcanovic 
et al. (2017)
RC 94.8 ± 78.7 Gastric 
function 
abnormalitis
PPI NR NR NR 67 60.4 ± 15.9 479/520 250 Early:late = 
1.34:1
NR 88 12 2.81 
(1.13–6.93)
NR 1. Retrospective database on university setting. 
2.  Multilevel mixed effects parametric survival analisys 
conducted for the association between PPI and IF 
3.  Multifactorial analysis detected bruxism (HR = 2.86), smoking 
(HR = 2.36, short implant length (HR = 1 to >10 mm 
HR = 0.39), prophylactic antibiotic regimen (HR = 0.49) and 
location (anterior maxilla as the highest HR = 1; anterior 
mandible the lowers HR = 0.53) 3. 
ASA I- II NSM N NR NR 932 3309 NR 93.5 4.5 1
Chrcanovic 
et al. (2017)
RC 90.11 ± 74.23 Depresive 
condition
SSRIs NR NR NR 18 55.9 ± 18.5 145/155 48 Early = 31.4%; 
late = 51.4%
NR 87.5 12.5 4.10 
(0.67–24.96)
NR 1. Retrospective data based on university setting. 
2. Kaplan Meier showed SS in the cumulative survival rate (p < 0.001)
3.  Multilevel mixed effects equations did not detect SS 
association with IF. 
4.  Multivariate generalized estimating equations logistic 
regression model showed SS association with IF and smooth 
implants (HR = 1; rough surface = HR = 0.08) and location 
(anterior maxilla presented the highest HR = 1; anterior 
mandible the lowest HR = 0.12) 
5. Time in function demonstrated to SS influence IF (p < 0.001)
ASA I- II NSM N N NR 282 883 96.5 3.3 1
Al- Sabbagh 
et al. (2014)
CC 84.6 Osteoporosis BP NR >3 Oral 20 515 40.9%/59.1% 472 N NR 100 0 0 NR  CC study conducted at the university setting - Lack of control 
for confoundings - No report on data regarding the control 
group - Poorly defined eligibility criteria ASA I- II NSM N 183 46 NR NR NR NR NR NR
Siebert et al. 
(2013)
PC 12 Osteoporosis Zoledronic 5 mg/year NR IV 12 54 ± 12 0%/100% 60 NR NR 100 0 0 NR Prospective case- control study on immediate placement 
therapy - Common implant characteristics: 3.7 × 16 mm 
- Patients received pre- implant therapy ATB - No mention on 
MBL, although authors state no SS difference between groups
ASA I- II NSM N N N 12 60 NR NR 100 0 0 NR
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TABLE  1 On the medication- related implant failure: systematic review [In PDF format, this table is best viewed in two-page mode]
Authors 
(year)
Study 
design
Mean 
follow- up
Systemic 
condition Medication Dosage (mg/ml)
Therapy 
length 
(months)
Administration 
method
Subjects 
(n) Age (years)
Gender 
(M/F)
Implants 
(n)
Failure 
(month)
Marginal 
bone loss 
(mm)
Implant 
survival 
rate(%)
Implant 
failure 
rate (%) HR (95% CI)
Biological 
complications Comments
Wu et al. 
(2016)
RC 17.1 ± 16.6 Hypertension AM (beta- bloquers - 18.9%, 
thiazide diuretics - 5.4%, 
ACE inhibitors - 29.7%, 
ARBs - 24.3%, others 
- 21.6%)
NR NR Oral 142 57.7 ± 12.1 375/353 327 NR NR 99.4 0.6 0.12 
(0.03–0.49)
NR 1.  BA was performed more often in AH drug users (OR = 0.71)
2.  Age, gender, implant length, implant torque, implant loading 
and BA did not affect SR
3. HT patients not taking AH drugs had a failure of 4.7%
4.  Smoking was associated with increased implant failure  
(HR: 3.59)
ASA I- II NSM N N N 586 1172 NR NR 95.9 4.1 1 NR
Alissa et al. 
(2009)
RCT 6 ASA I- II NSAIDs (Ibuprophen) 600 mg 4×/day 7 d Oral 29 NR NR 41 N 1.09 ± 0.99 100 0 NR 0 1.  The multiple linear regression test showed that MBL was not 
SS associated with: age, gender, anatomic location, treatment 
group and examinerNSM N N N 29 48 N 1.19 ± 0.96 100 0 NR 0
Jeffcoat 
et al. (1995)
RCT 12 ASA I- II NSAIDS (Flurbiprofen) 50 mg 2× day 3 mo Oral 29 47.2 NR N 0.65 100 0 NR NR 1.  Quantitative digital substraction radiography was used to 
assess bone mass loss 2.Placebo and low- dose flurbiprophen 
lost a mean of 11.2 ± 3.89 and 14.6 ± 3.69 mg, respectively.
3.  High- dose flurbiprophen lost a mean of 2.60 ± 4.13 mg
4. Smooth surface dental implants
Flurbiprofen 100 mg 2× day 3 mo Oral N 1.6 100 0 NR
NSM N N N N 1.1 100 0 NR
Winnett 
et al. (2014)
RC NR NC NSAIDS (Ibuprophen) 600 mg 4× day 2w Oral 60 NR NR 273 Early:72%; 
late:28%
NR 56 44 NR NR 1. Retrospective data based on university setting. 
2.  The NSAIDs experienced 3.2× more case of radiographic 
bone loss 1/2 and 1.9× greater than 1/2 of the implant height
NSM N N N 44 203 Early:65%; 
late:35%
62 38 NR
Urdaneta 
et al. (2011)
RC 70.7 Arthristis, 
CDV 
prevention
NSAIDS (Ibuprophen, 
celecoxib, acetylsalicydic, 
rofecoxib, nabumetone, 
naproxen, etodolac)
Ibuprophen (600–1600 mg), 
celecoxib (200 mg), 
acetylsalicydic (325 mg), 
rofecoxib (25 mg), nabumetone 
(500 mg), naproxen (375 mg), 
etodolac (400 mg)
Daily Oral 13 NR NR 61 NR 0.06 100 0 NR NR 1. Study on extra- short locking- taper implants 
2. Main goal was to analyze crestal bone gain 
3.  Crestal bone gain was significantly correlated with type of 
opposing structure, tooth, type of restoration, crown 
cemented on prefabricated titanium abutment, hydroxiapa-
tite coating, implant site and daily intake of NSADS (p = 0.04) 
4.  Similar bone gain was observed in men/woman, maxilla/
mandibleASA I- II NSM N N n 68 265 0.42 97.74 2.26 NR NR
Wu et al. 
(2016)
RC 16.6 ± 16.3 Gastric function 
abnormalitis
PPI NR NR Oral 58 56.6 ± 13.7 369/430 133 NR NR 93.2 6.8 2.73 
(1.10–6.78)
NR 1.  Large RC study with different implan ttypes, protocols and 
grafting procedures 
2. NSAIDs were taken more by PPI users (OR = 1.73) 
3. Smoking was associated with IF (p = 0.001) 
4.  Patients gender, age implant length, and bone augmentation 
had no significant association with IF
ASA I- II NSM N N n 741 1,640 96.8 3.2 1
Wu et al. 
(2014)
RC 36 Depressive 
condition
SSRIs (citalopram, dapoxetine, 
escitalopram, fluoxetine, 
fluvoxamine, indalpine, 
paroxetine, sertraline, 
venlafaxine, zimeline)
NR NR Oral 50 56.4 ± 13.7 198/292 94 4–14 mo NR 89.4 10.6 6.28 
(1.25–31.61)
NR 1.  Large RC study with different implan ttypes, protocols and 
grafting procedures 
2.  Smoking habit (p = 0.01)and small implant diameters 
(p = 0.02) were associated with higher IF 
3.  Bone augmentation was associated with higher implant 
failure 
ASA I- II NSM N N N 440 882 95.4 4.6 1
Reddy et al. 
(1990)
RCT 4 ASA I- II NSAIDS (Flurbiprofen) 100 mg 2× day 4 mo Oral NR NR NR NR NR NR 100 0 NR NR 1.  Main goal was to assess the peri- implant bone remodeling 
testing the feasability of digital substraction radiography 
2.  No data on patientients demographics nor implant 
characteristics 
3.  Individuals intaking the NSAIDs experienced greater 
peri- implant bone density during healing
NSM N N N 100 0 NR
Chrcanovic 
et al. (2017)
RC 94.8 ± 78.7 Gastric 
function 
abnormalitis
PPI NR NR NR 67 60.4 ± 15.9 479/520 250 Early:late = 
1.34:1
NR 88 12 2.81 
(1.13–6.93)
NR 1. Retrospective database on university setting. 
2.  Multilevel mixed effects parametric survival analisys 
conducted for the association between PPI and IF 
3.  Multifactorial analysis detected bruxism (HR = 2.86), smoking 
(HR = 2.36, short implant length (HR = 1 to >10 mm 
HR = 0.39), prophylactic antibiotic regimen (HR = 0.49) and 
location (anterior maxilla as the highest HR = 1; anterior 
mandible the lowers HR = 0.53) 3. 
ASA I- II NSM N NR NR 932 3309 NR 93.5 4.5 1
Chrcanovic 
et al. (2017)
RC 90.11 ± 74.23 Depresive 
condition
SSRIs NR NR NR 18 55.9 ± 18.5 145/155 48 Early = 31.4%; 
late = 51.4%
NR 87.5 12.5 4.10 
(0.67–24.96)
NR 1. Retrospective data based on university setting. 
2. Kaplan Meier showed SS in the cumulative survival rate (p < 0.001)
3.  Multilevel mixed effects equations did not detect SS 
association with IF. 
4.  Multivariate generalized estimating equations logistic 
regression model showed SS association with IF and smooth 
implants (HR = 1; rough surface = HR = 0.08) and location 
(anterior maxilla presented the highest HR = 1; anterior 
mandible the lowest HR = 0.12) 
5. Time in function demonstrated to SS influence IF (p < 0.001)
ASA I- II NSM N N NR 282 883 96.5 3.3 1
Al- Sabbagh 
et al. (2014)
CC 84.6 Osteoporosis BP NR >3 Oral 20 515 40.9%/59.1% 472 N NR 100 0 0 NR  CC study conducted at the university setting - Lack of control 
for confoundings - No report on data regarding the control 
group - Poorly defined eligibility criteria ASA I- II NSM N 183 46 NR NR NR NR NR NR
Siebert et al. 
(2013)
PC 12 Osteoporosis Zoledronic 5 mg/year NR IV 12 54 ± 12 0%/100% 60 NR NR 100 0 0 NR Prospective case- control study on immediate placement 
therapy - Common implant characteristics: 3.7 × 16 mm 
- Patients received pre- implant therapy ATB - No mention on 
MBL, although authors state no SS difference between groups
ASA I- II NSM N N N 12 60 NR NR 100 0 0 NR
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F IGURE  1 PRISMA flowchart of the screening process
Authors 
(year)
Study 
design
Mean 
follow- up
Systemic 
condition Medication Dosage (mg/ml)
Therapy 
length 
(months)
Administration 
method
Subjects 
(n) Age (years)
Gender 
(M/F)
Implants 
(n)
Failure 
(month)
Marginal 
bone loss 
(mm)
Implant 
survival 
rate(%)
Implant 
failure 
rate (%) HR (95% CI)
Biological 
complications Comments
Grant et al. 
(2008)
RC 48 Osteoporosis Prior to implant placement: 
Fosamax (66), Actonel (21), 
Boniva (2) After implant 
placement: Fosamax (27), 
Actonel (5) Boniva (1)
NR 38 Oral 115 40 0%/100% 468 <6 NR 99.5 0.5 NR NR Retrospective cohort study with poor data regarding implant 
outcomes - Patients were reached through mail to answer a 
survey to be examined - Implants in the case group had early 
failure - None of the 115 included in the case group had 
osteonecrosis as consequence of implant therapy - Diabetes 
and steroids could be other confounding factors 
ASA I- II N N N N 343 1450 NR NR 99 1 NR NR
Koka et al. 
(2010)
RC >36 Osteoporosis 
(32)/
osteopenia 
(18)
BP NR NR Oral 55 71 0%/100% 121 NR NR 99.17 0.83 NR NR Retrospective cohort study with vague data acquisition 
- Failures in the non- BP group ocurred concomitant to the 
intake of steroids, calcium and vitamin D and in smokers and 
diabetics - Failures in the BP group ocurred in patients 
intaking HRT- estrogen, cacium and vitamin D 
NR NSM N N N 82 66 166 NR NR 98.19 1.81 NR NR
Zahid et al. 
(2011)
RC 66 Osteoporosis BP 26 Oral 26 56 38.1%/62.9 51 <2 NR 94.11 5.88 NR NR Restrospective radiographic study - Poor descriptive and 
statistic analysis - Possible confounders: smoking (8.5% 
- OR = 1.28), bone graft (26.2 OR = 1.31) and thread exposure 
(10.9% - OR = 3.25) - Statistically significant associations were 
found between the use of BP and thread exposure (p = 0.001) 
- No cases of osteonecrosis as consequence of implant 
therapy were registered
ASA I- II N N N N 274 610 NR NR 97.1 2.6 NR NR
Memon et al. 
(2012)
RC 54 Osteoporosis Risedronate (23), 
Ibandronate (5), 
Alendronate (72)
NR <1 y (20), 
1–3 y (19), 
>3 y (15), 
unespeci-
fied (46)
Oral 100 66 ± 9 0%/100% 153 Early (10) 0.66 ± 0.70 93.5 6.5 NR NR Retrospective- chart based study - MBL evaluated at stage 2 
- MBL was only available from 73 patients in both groups 
- Multiple implant systems were evaluated - Failures by BP: 
Alendronate (6) ibandronate (3) and risedronate (10) - By 
proportion, ibandronate had the highest percentage of  
failures (25%)
ASA I- II N N N N 100 63 ± 9 132 Early (6) 0.80 ± 0.65 95.5 4.5 NR NR
Famili et al. 
(2014)
RC 12 Osteoporosis 
(21)/
osteoarthritis 
(1)
Fosamax/Boniva/Actonel NR NR Oral 22 ≥50	(120)/ 
<50 (91)
0%/100% 75 Early NR 98.7 1.3 NR NR Retrospective Unviersity- based study on females with/- out 
osteoporosis - Vague definition on success rate - Authors did 
not identify confounders - No data regarding the number of 
patients according to the BP - Lack on data in regards to the 
time period taking BP - Poor demographics
ASA I- II NSM N N N 98 272 N NR 100 0 NR NR
ASA, American Society of Anesthesiologists; BP, bisphosphonate; HRT, hormone replacement therapy; MBL,  marginal bone level; N, none;  
NR, not reported; NSM: no specific medications; RC, randomized, controlled.
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TABLE  2 Excluded papers based on full text evaluation
Author (year) Medication Reason for exclusion
Nisi et al. (2015) Bisphosphonate No data on implant 
failure
Holzinger et al. 
(2014)
Bisphosphonate Data on BRONJ after 
implant therapy
Lopez- Cedrun et al. 
(2013)
Bisphosphonate Data on BRONJ after 
implant therapy
Kim and Kwon et al. 
(2010)
Bisphosphonate Case report
Lazarovici et al. 
(2010)
Bisphosphonate Data on BRONJ after 
implant therapy
Kwon et al. (2014) Bisphosphonate Data on BRONJ after 
implant therapy
Grant et al. (2008) Bisphosphonate No data on implant 
failure
Favia et al. (2015) Bisphosphonate No data on implant 
failure
Mattheos et al. 
(2013)
Bisphosphonate Case report
Kwon et al. (2016) Bisphosphonate No data on implant 
failure
Kwon et al. (2016) Bisphosphonate Single- arm case study
Jacobsen et al. 
(2013)
Bisphosphonate No data on implant 
failure
Authors 
(year)
Study 
design
Mean 
follow- up
Systemic 
condition Medication Dosage (mg/ml)
Therapy 
length 
(months)
Administration 
method
Subjects 
(n) Age (years)
Gender 
(M/F)
Implants 
(n)
Failure 
(month)
Marginal 
bone loss 
(mm)
Implant 
survival 
rate(%)
Implant 
failure 
rate (%) HR (95% CI)
Biological 
complications Comments
Grant et al. 
(2008)
RC 48 Osteoporosis Prior to implant placement: 
Fosamax (66), Actonel (21), 
Boniva (2) After implant 
placement: Fosamax (27), 
Actonel (5) Boniva (1)
NR 38 Oral 115 40 0%/100% 468 <6 NR 99.5 0.5 NR NR Retrospective cohort study with poor data regarding implant 
outcomes - Patients were reached through mail to answer a 
survey to be examined - Implants in the case group had early 
failure - None of the 115 included in the case group had 
osteonecrosis as consequence of implant therapy - Diabetes 
and steroids could be other confounding factors 
ASA I- II N N N N 343 1450 NR NR 99 1 NR NR
Koka et al. 
(2010)
RC >36 Osteoporosis 
(32)/
osteopenia 
(18)
BP NR NR Oral 55 71 0%/100% 121 NR NR 99.17 0.83 NR NR Retrospective cohort study with vague data acquisition 
- Failures in the non- BP group ocurred concomitant to the 
intake of steroids, calcium and vitamin D and in smokers and 
diabetics - Failures in the BP group ocurred in patients 
intaking HRT- estrogen, cacium and vitamin D 
NR NSM N N N 82 66 166 NR NR 98.19 1.81 NR NR
Zahid et al. 
(2011)
RC 66 Osteoporosis BP 26 Oral 26 56 38.1%/62.9 51 <2 NR 94.11 5.88 NR NR Restrospective radiographic study - Poor descriptive and 
statistic analysis - Possible confounders: smoking (8.5% 
- OR = 1.28), bone graft (26.2 OR = 1.31) and thread exposure 
(10.9% - OR = 3.25) - Statistically significant associations were 
found between the use of BP and thread exposure (p = 0.001) 
- No cases of osteonecrosis as consequence of implant 
therapy were registered
ASA I- II N N N N 274 610 NR NR 97.1 2.6 NR NR
Memon et al. 
(2012)
RC 54 Osteoporosis Risedronate (23), 
Ibandronate (5), 
Alendronate (72)
NR <1 y (20), 
1–3 y (19), 
>3 y (15), 
unespeci-
fied (46)
Oral 100 66 ± 9 0%/100% 153 Early (10) 0.66 ± 0.70 93.5 6.5 NR NR Retrospective- chart based study - MBL evaluated at stage 2 
- MBL was only available from 73 patients in both groups 
- Multiple implant systems were evaluated - Failures by BP: 
Alendronate (6) ibandronate (3) and risedronate (10) - By 
proportion, ibandronate had the highest percentage of  
failures (25%)
ASA I- II N N N N 100 63 ± 9 132 Early (6) 0.80 ± 0.65 95.5 4.5 NR NR
Famili et al. 
(2014)
RC 12 Osteoporosis 
(21)/
osteoarthritis 
(1)
Fosamax/Boniva/Actonel NR NR Oral 22 ≥50	(120)/ 
<50 (91)
0%/100% 75 Early NR 98.7 1.3 NR NR Retrospective Unviersity- based study on females with/- out 
osteoporosis - Vague definition on success rate - Authors did 
not identify confounders - No data regarding the number of 
patients according to the BP - Lack on data in regards to the 
time period taking BP - Poor demographics
ASA I- II NSM N N N 98 272 N NR 100 0 NR NR
ASA, American Society of Anesthesiologists; BP, bisphosphonate; HRT, hormone replacement therapy; MBL,  marginal bone level; N, none;  
NR, not reported; NSM: no specific medications; RC, randomized, controlled.
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Author (year) Medication Reason for exclusion
Tam et al. (2014) Bisphosphonate Single- arm case study
Lazarovici et al. 
(2010)
Bisphosphonate Data on BRONJ after 
implant therapy
Shabestari et al. 
(2010)
Bisphosphonate Single- arm case study
Goss et al. (2010) Bisphosphonate Data on BRONJ after 
implant therapy
Bell and Bell (2010) Bisphosphonate Single- arm case study
Gomez- Moreno 
et al. (2016b)
Anticoagulant Report on bleeding 
complications
Gomez- Moreno 
et al. (2016a)
Anticoagulant Report on bleeding 
complications
Karbuda et al. 
(2007)
COX- 2 inhibitor Report on analgesic and 
inflammatory response
Chrcanovic et al. 
(2016c)
Anticoagulant Multivariate analysis
Chrcanovic et al. 
(2016a)
NSM Multivariate analysis
Chrcanovic et al. 
(2016b)
Anticoagulant Multivariate analysis
BRONJ, Bisphosphonate- related osteonecrosis of the jaw; COX, 
Cyclooxygenase; NSM, No- specific medication.
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odds ratio of 1.21. Hence, an effect of the experimental medication 
could not be concluded (p > .05 for the null of no effect) (Figure 4).
3.5 | Quality assessment
After the screening process, we found 13 studies included in the 
qualitative assessment that could be analyzed with NOS (Table S1). 
A Cohen’s kappa inter- rater agreement rate of .92 was reached. 
After discussing the disagreements between the examiners (AM and 
GAO), a mean NOS score of 6.38 ± 2.43 was obtained.
4  | DISCUSSION
4.1 | Principal findings
Although survival in implant dentistry does not represent a chal-
lenge anymore, failures and complications still occur (Brugger et al., 
2015). The present systematic review revealed an insight into the 
possible effect of some medications on implant failure. Interestingly, 
PPIs used to reduce the production of acid by blocking the enzyme 
in the wall of the stomach that produces acid (Colmenares & Pappas, 
2016) and SSRIs used for depression and anxiety conditions (Galli, 
Macaluso & Passeri, 2013) exhibited an increased risk of implant fail-
ures. On the other side, unexpectedly, the use of oral BPs for the 
treatment of osteoporosis did not yield significance when analyzing 
their impact on implant failure. This finding is of special interest as 
oral BPs intake was reported to be associated with a significantly 
higher risk to develop osteonecrosis of the jaw due to the blocking 
of osteoclastic activity (Edwards et al., 2007). To the best of authors’ 
knowledge, this systematic review was the first one in highlighting 
the potential implications of medications upon implant longevity. 
Nevertheless, findings from this study cannot be conclusive due to 
the studies’ design and consequently, the number of inherent uncon-
trolled confounders. Accordingly, it is encouraged to prospectively 
study the effect of these medications upon early and late implant 
failure controlling other known risk factors for the stability of the 
peri- implant tissues.
4.2 | Are our findings biologically plausible?
The effect and interaction of some medications with bone ho-
meostasis has been extensively documented in preclinical studies 
(David, Nguyen, Barbier & Baron, 1996; Galli et al., 2013; Haney & 
Warden, 2008; Insua et al., 2017; Nyman, Schroeder & Lindhe, 1979; 
Robinson, Tashjian & Levine, 1975; Rzeszutek, Sarraf & Davies, 2003; 
Vestergaard, 2008). Recently, in vivo clinical reports have been of 
great interest in the field of implant dentistry due to the likely role of 
these medications upon osseointegration (Winnett et al., 2016; Wu 
et al., 2014, 2016, 2017). The present meta- analysis yielded statisti-
cal significance to feature the possible relevance of PPIs and SSRIs 
on IF.
Proton pump inhibitors aim at inhibiting the acid output to the 
stomach for the treatment of gastroesophageal reflux or gastric ul-
cers. The underlying mechanism that could negatively impact osse-
ointegration leans on the impaired effective calcium uptake through 
the intestines (Kopic & Geibel, 2010, 2013). Calcium is an essential 
mineral for the proper formation and maintenance of the skeleton 
as it may impact upon the bone mineral density (Tai, Leung, Grey, 
Reid & Bolland, 2015). In point of fact, a calcium intake of at least 
1,000–1,200 mg/day has been recommended to minimize the risk of 
F IGURE  2  (a) Meta- analysis of mean and 95% confidence interval of implant failure for patients taking proton pump inhibitors (PPIs). (b) 
Meta- analysis of mean and 95% confidence interval of odds ratios for patients taking proton pump inhibitors (PPIs)
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F IGURE  4  (a) Meta-analysis of mean and 95% confidence interval of implant failure for patients taking bisphosphonates (BPs). (b) Meta-
analysis of mean and 95% confidence interval of odds ratios for patients taking bisphosphonates (BPs)
Study
Fixed effect model
Random effects model
Heterogeneity: I2 = 27%, τ2 = 0.2354, p = 0.24
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F IGURE  3  (a) Meta-analysis of mean and 95% confidence interval of implant failure for patients taking serum serotonin reuptake 
inhibitors (SSRIs). (b) Meta-analysis of mean and 95% confidence interval of odds ratios for patients taking serum serotonin reuptake 
inhibitors (SSRIs)
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osteoporosis (Tang, Brooks, Wetmore & Shireman, 2015). O’Connell, 
Madden, Murray, Heaney and Kerzner (2005) examined for 7 days 
the intake of omeprazole 20 mg QD and found out a reduced calcium 
absorption when compared to a placebo medication in postmeno-
pausal women. A further study confirmed that urine calcium excre-
tion was reduced when in- taking omeprazole 20 mg TD (Graziani 
et al., 1995). Hence, understanding the effect of PPIs on calcium re-
duction and the detrimental result upon bone homeostasis highlight 
the clinical implications of the intake of PPIs on IF.
Along the same lines, SSRIs used for depressive or anxiety con-
ditions have been further identified to play a pivotal role on the 
osteoblast/osteoclast balance. As such, serotonin can regulate os-
teoclast activation and differentiation as osteoclasts derive from 
hematopoietic cell precursors (Battaglino et al., 2004). As a mat-
ter of fact, the activity of the serotonin transporter and receptor is 
present in bone. Consequently, SSRIs have demonstrated to have 
detrimental effect on bone mineral density and trabecular microar-
chitecture through their anti- anabolic skeletal effects (Kahl et al., 
2006). For this reason, it might be hypothesized to negatively influ-
ence the process of osseointegration. Recently, a preclinical in vivo 
study has elucidated the effect of SSRIs on osteoblast differentia-
tion and bone regeneration in rats. Interestingly, SSRI medication 
significantly reduced osteogenic differentiation and mineralization 
with concomitant reduction of osteoblast marker genes including 
alkaline phosphatase, Osterix, and osteocalcin, indicating its puta-
tive impact on the regulation of bone metabolism (Nam et al., 2016). 
Hence, such cellular findings would be in concordance with the re-
sults obtained by Wu et al. (2014), who demonstrated that patients 
in- taking SSRIs experienced an increased risk of IF (hazard ratio: 
6.28; 95% confidence interval: 1.25–31.61; p = .03). In addition, it 
should also be considered that the higher risk of implant failures 
may is influenced as well by the psychological condition of the pa-
tient rather than by the intake of SSRI.
On the other side, medications reported in the literature to 
possibly interfere with osseointegration or bone homeostasis such 
as NSAIDS or oral BPs have failed to show statistical significance. 
As aforementioned, these findings must be cautiously interpreted, 
as there are other confounding factors such as the absence of an 
effect on implant survival due to the given dosages. The largest 
and longer term study analyzing failing osseointegration of 197 
implants revealed that patients using NSAIDs peri- operatively ex-
perienced 44% IF, while 38% IF rate was occurred in patients, who 
did not take NSAID peri- operatively. Moreover, the NSAIDs cohort 
experienced 3.2 times more cases of radiographic bone loss >30% 
of the overall height and 1.9 times more cases of cluster failures 
(Winnett et al., 2016). Accordingly, it might be speculated that the 
intake of peri- operative NSAIDs may inhibit the inflammatory bone 
metabolism, especially in vulnerable populations while having min-
imal clinical effect in healthy patient populations (Winnett et al., 
2016). In contrast, the use of AHTNs has been suggested to have 
a beneficial impact on implant longevity. The biological plausibil-
ity of this finding rests on the fact that AHTNs drugs can affect 
bone metabolism by inhibiting osteoclasts catabolic effects on 
bone by blocking their β2 adrenergic receptors (beta- bloquers), 
to enhance bone formation by increasing calcium absorption at 
the distal convoluted tubule (thiazides) or by shifting the balance 
toward bone formation by blocking the renin- angiotensin system 
(ACE inhibitors) (Wu et al., 2016). In addition, oral BPs did not show 
to substantially contribute to IF. This is an interesting finding, as 
this medication mainly used for osteoporosis or cancer therapy is 
likely the most widely documented medication affecting the skele-
tal bone characteristics (Brufsky & Mathew, 2015; Rachner, Khosla 
& Hofbauer, 2011; Sambrook & Cooper, 2006). Briefly, BPs inhibit 
the digestion of bone by promoting the apoptosis or cell death of 
osteoclast, thereupon decreasing the rate of bone resorption along 
the therapy (Migliorati, Siegel & Elting, 2006). One of the most 
common complications in our field has been the increased risk of 
osteonecrosis of the jaw as a consequence of dental extraction 
or otherwise oral surgery (Ruggiero et al., 2009). Authors want to 
reiterate that when interpreting these results must be exercised 
cautiousness due to the lack of homogeneity with regard to the 
dosage and timing in- taking oral BPs reported in the studies, but 
apparently seems not to represent a contraindication for implant 
therapy in osteoporotic patients. Contrarily, bone malignancies/
metastases involving the intake of intra- venous BPs represent an 
absolute contraindication for implant therapy.
4.3 | Limitations and future directions
The findings of the present study should be interpreted with great 
caution. First of all, due to the nature of the included study designs 
in the present systematic review, no “cause- effect” relationship 
can be established, but “association” and thus, findings from the 
present review encourage to investigate in a prospective manner 
the impact of medications on implant outcomes controlling other 
known confounders (i.e., smoking, plaque control, or other local and 
systemic contributing factors) that could potentially interfere in the 
implant stability. Moreover, the timing of implant failure must be 
adequately reported. In this sense, this would help to gain perspec-
tive on possible underlying mechanisms that elicit implant failure. 
Along these lines, it is encouraged to investigate the effect of poly-
medication on osseointegration and implant failure. Furthermore, 
a major limitation that was found when investigating the biological 
complications was the lack of standardization with regard to the 
definition of peri- implant disease. Hence, it is strongly advised to 
follow the guidelines recommended by the European Federation of 
Periodontology and the American Academy of Periodontology to 
report on biological complications using clinical and radiographic 
assessments.
5  | CONCLUSIONS
Findings from the present systematic review showed an association 
of proton pump inhibitors and selective serotonin reuptake inhibitors 
with implant failure. Hence, the effect of these medications should 
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be further investigated in future studies as potential confounders for 
implant outcomes.
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